Published in World J Hepatol on January 08, 2016
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine (2012) 6.01
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther (2009) 4.98
Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol (2007) 4.73
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol (2010) 1.67
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut (2012) 1.62
Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2012) 1.58
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (2014) 1.43
A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst (2009) 1.43
Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol (2011) 1.30
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res (2010) 1.29
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology (2013) 1.26
The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24
Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics (2011) 1.24
Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol (2012) 1.23
Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol (2011) 1.21
Metabolomics in diabetes research. J Endocrinol (2012) 1.20
Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem (2012) 1.16
New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med (2007) 1.15
Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Cancer Res (2012) 1.10
Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis (2011) 1.09
The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One (2011) 1.08
Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem (2011) 1.07
Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract (2010) 0.99
The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Sci Rep (2015) 0.98
NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Int J Cancer (2014) 0.98
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
Lipotoxicity in the liver. World J Hepatol (2013) 0.97
Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis. J Proteome Res (2011) 0.97
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2012) 0.96
Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Electrophoresis (2013) 0.94
¹H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis. World J Gastroenterol (2012) 0.94
A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J Proteome Res (2011) 0.92
Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med (2014) 0.92
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int (2014) 0.91
Metabolomics--a novel window into inflammatory disease. Swiss Med Wkly (2013) 0.91
Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. PLoS One (2014) 0.89
Serum 1H-NMR metabolomic fingerprints of acute-on-chronic liver failure in intensive care unit patients with alcoholic cirrhosis. PLoS One (2014) 0.89
Meta-analysis of the clinical value of danshen injection and huangqi injection in liver cirrhosis. Evid Based Complement Alternat Med (2013) 0.88
Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract (2013) 0.88
Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS. J Viral Hepat (2013) 0.87
Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med (2009) 0.87
Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. J Immunol Methods (2014) 0.86
Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2013) 0.86
Hepatitis B virus large surface protein: function and fame. Hepatobiliary Surg Nutr (2015) 0.86
Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology (2002) 0.84
Metabolomic Profiling of Autoimmune Hepatitis: The Diagnostic Utility of Nuclear Magnetic Resonance Spectroscopy. J Proteome Res (2014) 0.84
Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver Int (2014) 0.82
Urinary metabolite variation is associated with pathological progression of the post-hepatitis B cirrhosis patients. J Proteome Res (2012) 0.82
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection. J Viral Hepat (2014) 0.82
Epigenetic events in liver cancer resulting from alcoholic liver disease. Alcohol Res (2013) 0.81
Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 0.79
A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry. Chin Med J (Engl) (2011) 0.79
The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease. J Res Med Sci (2013) 0.79
Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy? Rev Med Virol (2014) 0.77
Future considerations for dendritic cell immunotherapy against chronic viral infections. Expert Rev Clin Immunol (2014) 0.76